Open Protocols

Protocol Name	Investigatory Role	Biomarkers	Data Collections
National Ovarian Cancer Early Detection Program Blood and Genetics	Coordinating	0	0

Closed Protocols

This person has no closed protocols at the present moment.

Publications

Publication Name	PubMed ID	Journal
[Lysophosphatidic acid as a potential target for treatment and molecular diagnosis of epithelial ovarian cancers].	19739275	Orv Hetil
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.	10739756	Am J Hum Genet
Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer.	19431095	IDrugs
Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients.	11675522	Oncologist
Is transvaginal ultrasound effective for screening asymptomatic women for the detection of early-stage epithelial ovarian carcinoma?	10831340	Gynecol Oncol
Localization of the activin signal transduction components in normal human ovarian follicles: implications for autocrine and paracrine signaling in the ovary.	12050229	J Clin Endocrinol Metab
Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells.	11306508	Cancer Res
Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women.	12429618	Clin Cancer Res
Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.	11474660	N Engl J Med
Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility.	12235007	Cancer Res
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.	14506139	Clin Cancer Res
The scientific basis of early detection of epithelial ovarian cancer: the National Ovarian Cancer Early Detection Program (NOCEDP).	11775458	Cancer Treat Res
Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction.	11426960	Gynecol Oncol
Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.	11377596	Lancet
Ultrasound and ovarian cancer.	11775447	Cancer Treat Res
Use of proteomic patterns in serum to identify ovarian cancer.	11867112	Lancet
Whole-abdominal radiation in endometrial carcinoma: an analysis of toxicity, patterns of recurrence, and survival.	11131490	Cancer J

Interests

Ovarian Cancer

Our Natioanl Ovarian Cancer Early Detection Program was specifically established to clinically apply the biochemical, genetic and molecular knowledge of ovarian carcinogenesis, invasion and metastasis to address the problem of detection of early rather than late stage epithelial ovarian cancer. The enhanced understanding of ovarian cancer biology has led to the identification and detection of specific genetic, molecular and serum biomarkers in women with ovarian cancer that may have clinical utility in the evaluation of women deemed at increased risk for the development of this disease. The metastatic process of cellular adhesion, migration, extracellular matrix degradation, invasion into host parenchyma, proliferation, and neovascularization (3-5) are influenced by numerous regulatory molecules, such as epidermal growth factor (EGF) and receptors (EGF-R/ErbB), urinary-type plasminogen activator (uPA) and receptor (uPAR), matrix metalloproteinases (MMP), telomerase and lysophospholipids (6-8). We recently found that EGFR activation regulates ovarian tumor cell adhesion, migration and upregulates proteinase expression and activation. Our preliminary data has found that lysophosphatidic acid (LPA) upregulates proteinase (uPA, MMP) expression and activation and enhances invasiveness. Using this broad scientific foundation we plan to evaluate serum and plasma for lysophospholipids (such as LPA, LPI and LPC), EGFR/ERB1, MMPs, and uPAR. The newly developed Ovarian Pap test will be performed on asymptomatic women at increased risk to provide cytological samples for pathological examination as well as molecular and genetic analysis and biochemical and cellular assays using organ culture techniques. Increased risk is assigned to those women with either a personal history of breast cancer (4X increase), a family history of affected first degree relatives (2-7x increase), membership within a recognized inherited malignancy syndrome (40-60% increase) or the presence of an inherited BRCA mutation (16-100%). The clinical application of this research proposal will be the evaluation of newly developed molecular, genetic and biochemical assays for the accurate detection of early rather than late stage disease in asymptomatic women at increased risk for the development of ovarian cancer.

To update protocols, publications, biomarkers, or science data, please contact the Data Management and Coordinating Center.

Site

Mount Sinai Medical Center

Degree(s)

M.D.

Email

david.fishman@mssm.edu

Person ID

1003

EDRN Title

EDRN Associate Member

Note

To update contact information, please visit the Data Management and Coordinating Center .